<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Med</journal-id><journal-id journal-id-type="iso-abbrev">Mol Med</journal-id><journal-title-group><journal-title>Molecular Medicine</journal-title></journal-title-group><issn pub-type="ppub">1076-1551</issn><issn pub-type="epub">1528-3658</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39891099</article-id><article-id pub-id-type="pmc">PMC11786360</article-id><article-id pub-id-type="publisher-id">1097</article-id><article-id pub-id-type="doi">10.1186/s10020-025-01097-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>LRP11 facilitates lipid metabolism and malignancy in hepatocellular carcinoma by stabilizing RACK1 through USP5 regulation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liang</surname><given-names>Litao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jia</surname><given-names>Wenbo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Jinyi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Yanzhi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Deming</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Wenhu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Chao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ling</surname><given-names>Xiangyu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lv</surname><given-names>Qingpeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ai</surname><given-names>Xiaoming</given-names></name><address><email>aixiaoming0503@163.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kong</surname><given-names>Lianbao</given-names></name><address><email>lbkong@njmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ding</surname><given-names>Wenzhou</given-names></name><address><email>dingwenzhou@njmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04py1g812</institution-id><institution-id institution-id-type="GRID">grid.412676.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1799 0784</institution-id><institution>Hepatobiliary Center, </institution><institution>The First Affiliated Hospital of Nanjing Medical University, </institution></institution-wrap>300 Guangzhou Road, Nanjing, Jiangsu China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02drdmm93</institution-id><institution-id institution-id-type="GRID">grid.506261.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 7839</institution-id><institution>Key Laboratory of Liver Transplantation, Key Laboratory of Hepatobiliary Cancers, </institution><institution>Chinese Academy of Medical Sciences, National Health Commission (NHC, </institution></institution-wrap>Nanjing, Jiangsu China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/028pgd321</institution-id><institution-id institution-id-type="GRID">grid.452247.2</institution-id><institution>Department of Hepatobiliary Pancreatic Spleen Surgery, </institution><institution>Affiliated Hospital of Jiangsu University, </institution></institution-wrap>No.438 Jiefang Road, Zhenjiang, Jiangsu China </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>31</volume><elocation-id>35</elocation-id><history><date date-type="received"><day>21</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and a major public health challenge. Lipid metabolism plays a crucial role in the metabolic reprogramming observed in HCC, although the underlying mechanisms are still being elucidated. Nile red staining and lipid assays showed that LRP11 knockdown significantly reduces lipid accumulation in HCC cells, with a concurrent decrease in key lipid metabolism markers such as FSAN, ACLY and ACSL4, as demonstrated by Western blotting. Mass spectrometry (MS) and co-immunoprecipitation (Co-IP) revealed that LRP11 recruits USP5, enhancing USP5-mediated deubiquitination of RACK1. Truncation analysis identified LRP11 residues 309&#x02013;500 as critical for interaction with the RACK1 residues 91&#x02013;231. These findings suggest that LRP11 may influence lipid metabolism and progression in HCC through USP5-mediated stabilization of RACK1. Based on these results, LRP11 emerges as a potential target for further exploration in HCC therapy. Targeting LRP11 or disrupting its interactions with USP5 or RACK1 could offer new avenues for treatment, though additional research is required to validate these therapeutic possibilities.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s10020-025-01097-6.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>LRP11</kwd><kwd>Hepatocellular carcinoma</kwd><kwd>Deubiquitination</kwd><kwd>Lipid metabolism</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81871260</award-id><principal-award-recipient><name><surname>Kong</surname><given-names>Lianbao</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University</institution></funding-source><award-id>PY2022007</award-id><principal-award-recipient><name><surname>Ding</surname><given-names>Wenzhou</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Feinstein Institute for Medical Research 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par7">Primary hepatocellular carcinoma (HCC) is one of the six most common cancers globally and ranks third in cancer-related mortality, making it a significant global healthcare challenge (Llovet et al. <xref ref-type="bibr" rid="CR16">2021</xref>; Sung et al. <xref ref-type="bibr" rid="CR27">2021</xref>) Despite advancements in comprehensive treatment strategies, including surgical resection, ablation, chemoembolization, liver transplantation, and systemic therapies, the prognosis for HCC patients remains poor (Llovet et al. <xref ref-type="bibr" rid="CR16">2021</xref>). The asymptomatic nature of early-stage HCC and the lack of effective diagnostic methods often result in late-stage diagnosis, contributing to high mortality rates and poor patient prognosis. Therefore, understanding the molecular mechanisms underlying the development and progression of HCC is essential for identifying potential therapeutic targets, which may contribute to improving early diagnosis and patient outcomes in the future.</p><p id="Par8">Our study focuses on low-density lipoprotein receptor-related protein 11 (LRP11), a member of the low-density lipoprotein receptor (LDLR) family (Roslan et al. <xref ref-type="bibr" rid="CR25">2019</xref>). The LDLR family consists of transmembrane proteins encoding single-pass receptors, and previous studies have shown that LDLR family genes are involved in various cellular processes and tumor progression (He et al. <xref ref-type="bibr" rid="CR9">2023</xref>; Lin et al. <xref ref-type="bibr" rid="CR13">2024</xref>; Liu et al. <xref ref-type="bibr" rid="CR14">2021</xref>, <xref ref-type="bibr" rid="CR15">2024</xref>; Rong et al. <xref ref-type="bibr" rid="CR24">2022</xref>). However, studies on LRP11 in tumorigenesis are limited, with evidence suggesting its involvement in the malignant progression of prostate and cervical cancers (Gan et al. <xref ref-type="bibr" rid="CR7">2020</xref>; Gu et al. <xref ref-type="bibr" rid="CR8">2023</xref>). To date, the mechanisms by which LRP11 contributes to HCC remain unreported, making it a critical area for further investigation in understanding HCC progression.</p><p id="Par9">Receptor for activated C kinase 1 (RACK1) is a member of the tryptophan-aspartate repeat (WDR) protein family (Schapira et al. <xref ref-type="bibr" rid="CR26">2017</xref>). Previous studies have shown that RACK1 is a multifunctional scaffold protein that interacts with various receptor proteins and protein kinases, thereby regulating key cellular activities such as signal transduction, cell adhesion, and migration, in both physiological and pathological conditions (Li and Xie <xref ref-type="bibr" rid="CR11">2015</xref>; Cao et al. <xref ref-type="bibr" rid="CR2">2019</xref>; Duff and Long <xref ref-type="bibr" rid="CR6">2017</xref>). Dysregulation of RACK1 expression influences tumorigenesis, potentially promoting proliferation, metastasis, invasion, and chemoresistance in various cancers, including ovarian, breast, lung, osteosarcoma, hepatocellular, cervical, and oral squamous cell carcinoma (Pi et al. <xref ref-type="bibr" rid="CR22">2023</xref>; Tian et al. <xref ref-type="bibr" rid="CR28">2023</xref>; Wang et al. <xref ref-type="bibr" rid="CR30">2022</xref>; Xia et al. <xref ref-type="bibr" rid="CR33">2023</xref>; Peng et al. <xref ref-type="bibr" rid="CR21">2024</xref>; Wu et al. <xref ref-type="bibr" rid="CR32">2020</xref>; Dan et al. <xref ref-type="bibr" rid="CR3">2020</xref>). Furthermore, evidence suggests that RACK1 regulation is closely associated with the ubiquitin&#x02013;proteasome system (Peng et al. <xref ref-type="bibr" rid="CR21">2024</xref>; Yu et al. <xref ref-type="bibr" rid="CR36">2021</xref>; Ou et al. <xref ref-type="bibr" rid="CR20">2022</xref>; Li et al. <xref ref-type="bibr" rid="CR12">2023</xref>). Zhouxia Ke et al. demonstrated that TRIM26 interacts with RACK1 and promotes its degradation through ubiquitination (Xia et al. <xref ref-type="bibr" rid="CR33">2023</xref>). Additionally, SMURF2 adds K6, K33, and K48 ubiquitin chains to RACK1, leading to its ubiquitination and instability (Pi et al. <xref ref-type="bibr" rid="CR22">2023</xref>). Nevertheless, the exact mechanisms by which RACK1 regulates the malignant progression of HCC remain unclear, highlighting the need for further investigation to explore its potential role in HCC.</p><p id="Par10">In this study, we show that LRP11 is upregulated in HCC and is correlated with poor prognosis. Our data suggest that LRP11 may promote HCC cell proliferation and migration in both in vitro and in vivo models. Mechanistically, LRP11 appears to interact with RACK1, potentially facilitating its deubiquitination via USP5, thereby stabilizing RACK1 protein levels. This interaction may contribute to enhanced HCC proliferation and invasion. These findings propose a novel mechanism by which LRP11 may influence HCC progression, and targeting the LRP11-RACK1 axis could provide a potential avenue for further exploration in HCC treatment.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Bioinformatics analysis</title><p id="Par11">Gene expression levels, prognostic significance, and pathological grading in HCC and normal tissues were analyzed using HCC sample data from The Cancer Genome Atlas (TCGA) via the GEPIA (gepia.cancer-pku.cn) and UALCAN (ualcan.path.uab.edu) databases.</p></sec><sec id="Sec4"><title>Hepatocellular carcinoma tissue samples</title><p id="Par12">The HCC and adjacent non-tumor tissues used in this study were obtained from the Hepatobiliary Center of the First Affiliated Hospital of Nanjing Medical University. All tissue samples were collected with written informed consent from the patients and were approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University.</p></sec><sec id="Sec5"><title>RNA sequencing</title><p id="Par13">Total RNA was extracted from Hep3B cells in the negative control and LRP11-OE groups using TRIzol reagent (Invitrogen, California, USA). The purity and concentration of total RNA were measured using a NanoDrop 2000 spectrophotometer (Thermo Scientific, MA, USA). RNA-seq analysis was conducted by Hongxu Biotechnology Company (Shanghai, China).</p></sec><sec id="Sec6"><title>IP combined with mass spectrometry</title><p id="Par14">Total protein was extracted from Hep3B cells, and immunoprecipitation (IP) was performed using an anti-LRP11 antibody (sc-514698, Santa Cruz) and protein A/G agarose beads (Thermo Scientific, MA, USA) as described above. Mass spectrometry analysis was conducted by BGI Tech Solutions Co., Ltd. (BGI, Shenzhen, Guangdong, China).</p></sec><sec id="Sec7"><title>Co-immunoprecipitation (Co-IP) assay</title><p id="Par15">The collected Hep3B cells and HEK293T cells transfected with His-LRP11, Flag-RACK1, and HA-USP5 were resuspended in 1&#x000a0;mL of RIPA protein lysis buffer containing 1% protease inhibitor and incubated on ice for a minimum of 30&#x000a0;min. The supernatants were then harvested and incubated with the respective primary antibodies or IgG at 4&#x000a0;&#x000b0;C for 24&#x000a0;h. Protein A and G agarose beads (Thermo Scientific, MA, USA) were subsequently added, and the mixture was incubated at 4&#x000a0;&#x000b0;C for an additional 3&#x000a0;h. The beads were washed five times with PBS buffer, and 40 &#x003bc;L of sample loading buffer was added followed by boiling for 5&#x000a0;min. Western blot analysis was performed on the processed samples. The following antibodies were utilized: LRP11 (sc-514698, Santa Cruz, 1:200 dilution), USP5 (10473-1-AP, Proteintech, 1:300 dilution), RACK1 (27592-1-AP, Proteintech, 1:250 dilution), His-tag (66005-1-Ig, Proteintech, 1:200 dilution), Flag-tag (20543-1-AP, Proteintech, 1:200 dilution), and HA-tag (51064-2-AP, Proteintech, 1:200 dilution).</p></sec><sec id="Sec8"><title>Data analysis</title><p id="Par16">Statistical analyses were performed using SPSS (version 19.0; SPSS, New York, USA) and GraphPad Prism 8.0 (GraphPad Software, California, USA). A two-tailed Student&#x02019;s t-test was used to assess differences between two groups. Fisher's exact test was employed to determine the association between LRP11 expression levels and clinicopathological parameters in HCC patients. Spearman&#x02019;s correlation analysis was used to evaluate the correlation between LRP11 and MAZ expression. All experiments were repeated at least three times independently, and data are presented as mean&#x02009;&#x000b1;&#x02009;standard deviation. Statistical significance was set at p&#x02009;&#x0003c;&#x02009;0.05 (n.s.&#x02009;=&#x02009;not significant, *p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01, ***p&#x02009;&#x0003c;&#x02009;0.001). All data collected were included in the final statistical analysis.</p><p id="Par17">Additional materials and methods are provided in the Supplementary materials and methods.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>LRP11 upregulation is associated with HCC progression and poor prognosis</title><p id="Par18">To further investigate key pathogenic factors in HCC, we analyzed the GSE14520 dataset and GEPIA database, LRP11 expression was found to be elevated in HCC tissues compared to non-tumor tissues. Analysis from GEPIA (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A) and UALCAN (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B) showed that higher LRP11 levels correlated with increased histological grade and reduced overall and disease-free survival (n&#x02009;=&#x02009;364) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C, <xref rid="Fig1" ref-type="fig">D</xref>). This suggests that LRP11 may act as an oncogene in HCC. Meanwhile, related studies have shown that LRP11 is involved in the malignant progression of various tumors, but its role in hepatocellular carcinoma remains unclear. Therefore, we first assessed the expression of LRP11 in HCC tissues. RT-qPCR revealed significantly higher LRP11 mRNA levels in 60 HCC samples compared to paired non-tumor tissues (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>E-F). Western blot analysis of 18 paired samples confirmed LRP11 protein upregulation in HCC tissues (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>G), demonstrating the consistency between mRNA and protein expression. Immunohistochemistry in six pairs of HCC and non-tumor tissues further supported these results (F<xref rid="Fig1" ref-type="fig">i</xref>g.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>H&#x02013;I). Additionally, LRP11 expression was positively correlated with tumor size and stage (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). These findings indicate that LRP11 may be a potential marker of HCC progression and poor prognosis, warranting further investigation as a possible prognostic biomarker or therapeutic target.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>LRP11 upregulation is associated with HCC progression and poor prognosis. <bold>A</bold> The expression of LRP11 in TCGA-LIHC dataset. <bold>B</bold> Expression of LRP11 in LIHC on tumor grade. <bold>C</bold> The overall survival of patient in LRP11-low or LRP11-high expression group. <bold>D</bold> The disease-free survival of LIHC.&#x000a0;n&#x02009;=&#x02009;264. <bold>E&#x02013;F</bold> RT-qPCR analysis of LRP11 mRNA expression in HCC tissues and paracancerous tissues. <bold>G</bold> Western blot assay was conducted to explore the protein levels of LRP11 in HCC tissues and matched normal tissues. <bold>H-I</bold> Immunohistochemical staining of LRP11 protein expression in human HCC tissues (Case1:T1N0M0, Case2 and Case3: T2N0M0) and their corresponding paracancerous tissue samples. Scale bar, 50&#x000a0;&#x003bc;m. All data are expressed as the mean&#x02009;&#x000b1;&#x02009;SD of values from experiments performed in triplicate. *P&#x02009;&#x0003c;&#x02009;0.05, **P&#x02009;&#x0003c;&#x02009;0.01, ***P&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="10020_2025_1097_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Correlation between LRP11 score in HCC and clinicopathological factors</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Clinicopathological factors</th><th align="left">No. of patients</th><th align="left" colspan="2">LRP11</th><th align="left" rowspan="2">P value</th></tr><tr><th align="left">n&#x02009;=&#x02009;60</th><th align="left">High</th><th align="left">Low</th></tr></thead><tbody><tr><td align="left">Gender</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Male</td><td align="left">39</td><td align="left">19</td><td align="left">20</td><td align="left" rowspan="2">0.787</td></tr><tr><td align="left">&#x000a0;Female</td><td align="left">21</td><td align="left">11</td><td align="left">10</td></tr><tr><td align="left">Age (years)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x0003c;&#x02009;60</td><td align="left">41</td><td align="left">22</td><td align="left">19</td><td align="left" rowspan="2">0.405</td></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;60</td><td align="left">19</td><td align="left">8</td><td align="left">11</td></tr><tr><td align="left">AFP</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02264;&#x02009;20</td><td align="left">22</td><td align="left">14</td><td align="left">8</td><td align="left" rowspan="2">0.107</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;20</td><td align="left">16</td><td align="left">16</td><td align="left">22</td></tr><tr><td align="left">HBsAg</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td align="left">16</td><td align="left">7</td><td align="left">9</td><td align="left" rowspan="2">0.559</td></tr><tr><td align="left">&#x000a0;Positive</td><td align="left">44</td><td align="left">23</td><td align="left">21</td></tr><tr><td align="left">Tumor number</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Single</td><td align="left">48</td><td align="left">22</td><td align="left">26</td><td align="left" rowspan="2">0.333</td></tr><tr><td align="left">&#x000a0;Multiple</td><td align="left">12</td><td align="left">8</td><td align="left">4</td></tr><tr><td align="left">Tumor size in cm</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02264;&#x02009;5</td><td align="left">28</td><td align="left">10</td><td align="left">18</td><td align="left" rowspan="2">0.038*</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;5</td><td align="left">32</td><td align="left">20</td><td align="left">12</td></tr><tr><td align="left">TNM stage</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;I</td><td align="left">35</td><td align="left">13</td><td align="left">22</td><td align="left" rowspan="2">0.018*</td></tr><tr><td align="left">&#x000a0;II&#x02013;III</td><td align="left">25</td><td align="left">17</td><td align="left">8</td></tr><tr><td align="left">Microvascular invasion</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">19</td><td align="left">8</td><td align="left">11</td><td align="left" rowspan="2">0.405</td></tr><tr><td align="left">&#x000a0;No</td><td align="left">41</td><td align="left">22</td><td align="left">19</td></tr></tbody></table><table-wrap-foot><p><italic>AFP</italic> alpha-fetoprotein, <italic>HBsAg</italic> hepatitis B surface antigen</p><p>*p&#x02009;&#x0003c;&#x02009;0.05; **p&#x02009;&#x0003c;&#x02009;0.01</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title><italic>LRP11 promotes malignant progression of HCC </italic>in vitro</title><p id="Par19">To assess the role of LRP11 in HCC, we extracted protein and mRNA from the normal hepatocyte cell line HHL-5 and the HCC cell lines (SK-Hep1, Hep3B, Huh7, YY-8103, MHCCLM3, HepG2, MHCC97L) for comparison. LRP11 expression levels were then analyzed using Western blot and RT-qPCR (Fig. S1A). LRP11 expression was significantly higher in HCC cell lines compared to the normal hepatocytes, with the highest expression observed in Huh7 cells and the lowest in Hep3B cells. LRP11 overexpression was induced in Hep3B cells, while LRP11 knockdown (sh-LRP11#1, sh-LRP11#2) was achieved in Huh7 cells. Overexpression and knockdown efficiency were confirmed at both mRNA and protein levels (Fig. S1B-C). EdU (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A), colony formation (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B), and CCK-8 assays (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C) demonstrated that LRP11 knockdown significantly inhibited cell proliferation, while its overexpression enhanced it. Transwell assays (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D) and Wound healing assays (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>E) revealed that LRP11 knockdown suppressed, while overexpression promoted, cell migration and invasion. These results suggest that LRP11 may play a role in the malignant progression of HCC.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>LRP11 promotes malignant progression of HCC in vitro.<bold> A</bold> Cell proliferation in HCC cells post-transfection with sh-NC, sh-LRP11#1, sh-LRP11#2, Vector, or LRP11-OE was evaluated using an EdU assay. Scale bar, 50&#x000a0;&#x003bc;m. <bold>B</bold> Cell proliferation was detected by knocking down LRP11 or overexpression LRP11 using colony formation assays. <bold>C</bold> Using CCK-8 assays detected the HCC cell's proliferation ability.<bold> D</bold> The transwell assay of HCC cells transfected with different plasmids. Scale bar, 500&#x000a0;&#x003bc;m. <bold>E</bold> Wound healing assay assessed the migratory capacity of Huh7 and Hep3B cells post-transfection with different plasmids. Scale bar, 100&#x000a0;&#x003bc;m. All data are expressed as the mean&#x02009;&#x000b1;&#x02009;SD of values from experiments performed in triplicate. *P&#x02009;&#x0003c;&#x02009;0.05, **P&#x02009;&#x0003c;&#x02009;0.01, ***P&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="10020_2025_1097_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec12"><title>LRP11 promotes lipid metabolism in HCC cells</title><p id="Par20">To investigate the mechanism by which LRP11 promotes HCC progression, RNA-seq in LRP11-overexpressing Hep3B cells identified 1,234 upregulated genes compared to controls (Fig. S1D). Sankey diagram analysis highlighted metabolic pathways, particularly lipid metabolism, as the most affected by LRP11 overexpression (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A). Complementing these findings, KEGG analysis further implicated fatty acid metabolism and degradation as key pathways impacted by LRP11 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). Pearson correlation analysis using Timer2.0 database showed significant positive correlations between LRP11 and key lipogenic enzymes, including ACACA (r&#x02009;=&#x02009;0.396, p&#x02009;&#x0003c;&#x02009;0.0001), ACLY (r&#x02009;=&#x02009;0.513, p&#x02009;&#x0003c;&#x02009;0.0001), ACSL4 (r&#x02009;=&#x02009;0.226, p&#x02009;&#x0003c;&#x02009;0.0001), and FASN (r&#x02009;=&#x02009;0.196, p&#x02009;&#x0003c;&#x02009;0.0001) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C), all of which play crucial roles in lipid metabolism and fatty acid synthesis. RT-qPCR (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>D) and Western blot (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>G) confirmed decreased lipogenic enzyme expression in LRP11-knockdown Huh7 cells and increased expression in LRP11-overexpressing Hep3B cells. LRP11 knockdown reduced triglyceride and cholesterol levels, while overexpression increased them (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>E, <xref rid="Fig3" ref-type="fig">F</xref>). Nile red staining demonstrated reduced lipid accumulation in LRP11-knockdown cells, whereas overexpression enhanced lipid accumulation (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>H). Taken together, these results suggest that LRP11 may play a significant role in regulating lipid metabolism and fatty acid synthesis in HCC cells, potentially contributing to the malignant progression of HCC.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>LRP11 promotes lipid metabolism in HCC cells.<bold> A</bold> Sankey diagram showing the trajectories of metabolite data flow across multiple pathways. <bold>B</bold> KEGG pathway enrichment analysis of the upregulated genes. <bold>C</bold> Scatter plot analysis of the correlation between LRP11 mRNA levels and ACACA, ACLY, ACSL4, and FASN in the Timer2.0 database. <bold>D</bold> RT-qPCR analysis of the mRNA expression of lipogenic enzyme genes ACACA, ACLY, ACSL4, and FASN in Huh7 and Hep3B cells. <bold>E&#x02013;F</bold> Measurement of triglyceride and cholesterol levels in Huh7 and Hep3B cells.<bold> G</bold> Determination of lipogenic enzyme protein levels in Huh7 and Hep3B cells by Western blotting. <bold>H</bold> Measurement of intracellular neutral lipids in Huh7 and Hep3B cells using Nile red and DAPI double staining. Scale bar, 50&#x000a0;&#x003bc;m. This was followed by quantifying the mean fluorescence intensity of Nile red staining for each cell line. All data are expressed as the mean&#x02009;&#x000b1;&#x02009;SD of values from experiments performed in triplicate. *P&#x02009;&#x0003c;&#x02009;0.05, **P&#x02009;&#x0003c;&#x02009;0.01, ***P&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="10020_2025_1097_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec13"><title>MAZ upregulates LRP11 in HCC</title><p id="Par21">To investigate the mechanism behind LRP11 overexpression in HCC, we used JASPAR, PROMO, GTRD, and hTFtarget databases to identify potential transcription factors that could activate LRP11 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A). MAZ, YY1, and VDR were identified as candidates. GEPIA database analysis identified that among the candidate transcription factors, MAZ expression is significantly elevated in HCC compared to non-tumorous tissues (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B), while VDR and YY1 showed no significant differences in expression (Fig. S2A-B). Additionally, MAZ(Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C), VDR(Fig. S2C), and YY1(Fig. S2D) expression levels positively correlate with LRP11 mRNA expression. In addition, a positive correlation between MAZ and LRP11 mRNA expression was validated in 60 HCC tissue samples from our cohort (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>D). Western blot analysis demonstrated that MAZ knockdown resulted in a decreased LRP11 protein level (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>E). Consistently, RT-qPCR assays confirmed that silencing MAZ significantly reduced LRP11 expression in HCC cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>F), whereas knockdown of YY1 and VDR had no discernible effect on LRP11 mRNA levels (Fig. S2E-F), highlighting MAZ as the key regulator of LRP11 expression. These results suggest that MAZ may act as a potential transcriptional regulator of LRP11 in HCC. ChIP assays provided evidence of MAZ binding to the LRP11 promoter (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>G, <xref rid="Fig4" ref-type="fig">H</xref>), and JASPAR predicted two MAZ binding sites (MBS1 and MBS2) (F<xref rid="Fig4" ref-type="fig">i</xref>g.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>I). Dual-luciferase reporter assays with site-directed mutations in the LRP11 promoter showed that mutation of MBS1 abolished MAZ-induced LRP11 transcription (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>J). These findings support the hypothesis that MAZ could influence LRP11 transcription through promoter binding, potentially contributing to LRP11 overexpression in HCC.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>MAZ upregulates LRP11 in HCC.<bold> A</bold> Bioinformatics analysis identified MAZ, YY1, VDR as potential transcription factors driving LRP11 expression. <bold>B</bold> mRNA expression of MAZ in HCC from the GEPIA database. <bold>C</bold> Pearson correlation analysis shows a positive correlation between LRP11 and MAZ mRNA in the TCGA dataset. <bold>D</bold> Pearson correlation analysis shows a positive correlation between LRP11 and MAZ mRNA in the HCC tissue samples. <bold>E, F</bold> After MAZ knockdown, LRP11 mRNA and protein levels were reduced. <bold>G-H</bold> Chromatin immunoprecipitation (ChIP) combined with qRT-PCR and PCR provided evidence of MAZ binding to the promoter region of the LRP11 gene.<bold> I</bold> Putative MAZ binding sites (MBS1 and MBS2) were identified in the promoter region of the LRP11 gene. <bold>J</bold> Dual-luciferase reporter assays showed that mutation of MBS1 disrupted its ability to regulate the LRP11 promoter region. A red "X" within the binding region indicates the altered MAZ binding sequence. All data are expressed as the mean&#x02009;&#x000b1;&#x02009;SD of values from experiments performed in triplicate. *P&#x02009;&#x0003c;&#x02009;0.05, **P&#x02009;&#x0003c;&#x02009;0.01, ***P&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="10020_2025_1097_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec14"><title><italic>LRP11 promotes HCC growth, metastasis, and lipid synthesis </italic>in vivo</title><p id="Par22">To evaluate the effects of LRP11 on HCC in vivo, we established subcutaneous xenograft and lung metastasis models using Huh7 and Hep3B cells stably transfected with either LRP11 knockdown (sh-LRP11#1, sh-LRP11#2), overexpression (LRP11-OE), or control constructs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A). In the xenograft model, tumor size, weight, and proliferation rate were significantly reduced in the sh-LRP11 group compared to controls, while LRP11 overexpression had the opposite effect (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>B, <xref rid="Fig5" ref-type="fig">C</xref>). IHC and Nile red staining showed reduced LRP11, KI-67, and lipid accumulation with LRP11 knockdown, and increased levels with LRP11 overexpression (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>D). In the lung metastasis model, LRP11 knockdown (sh-LRP11) significantly reduced both the size and number of metastatic nodules, as confirmed by H&#x00026;E staining, while LRP11 overexpression (LRP11-OE) led to an increase in both metastatic burden and nodule size (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>E, <xref rid="Fig5" ref-type="fig">F</xref>). Survival analysis revealed that mice injected with sh-LRP11 cells had prolonged overall survival (OS), while LRP11-OE mice had worse outcomes (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>G, <xref rid="Fig5" ref-type="fig">H</xref>). These findings suggest that LRP11 promotes HCC growth, metastasis, and lipid synthesis in vivo, suggesting that LRP11 may serve as a potential therapeutic target for limiting tumor progression and metastasis in HCC.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>LRP11 promotes HCC growth, metastasis, and lipid synthesis in vivo<bold>.</bold>
<bold>A</bold> Images of subcutaneous xenograft tumors from Huh7 (sh-NC, sh-LRP11#1, sh-LRP11#2) and Hep3B (Vector, LRP11-OE) cells. <bold>B</bold> Weight of the subcutaneous tumors. <bold>C</bold> Subcutaneous tumor volume growth curve. <bold>D</bold> H&#x00026;E, Ki67, LRP11 IHC staining, and Nile red staining in xenograft tumors. Scale bar, 50&#x000a0;&#x003bc;m. <bold>E</bold> Images of lung metastases from Huh7 and Hep3B cells. Scale bar, 2&#x000a0;mm. Along with H&#x00026;E staining of the metastatic lesions. Scale bar, 50&#x000a0;&#x003bc;m. <bold>F</bold> Quantification of lung metastases. <bold>G, H</bold> Kaplan&#x02013;Meier survival curves of mice (n&#x02009;=&#x02009;10). All data are expressed as the mean&#x02009;&#x000b1;&#x02009;SD of values from experiments performed in triplicate. *P&#x02009;&#x0003c;&#x02009;0.05, **P&#x02009;&#x0003c;&#x02009;0.01, ***P&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="10020_2025_1097_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec15"><title>LRP11 interacts with RACK1</title><p id="Par23">To further explore the mechanism by which LRP11 regulates HCC progression, immunoprecipitation-mass spectrometry (IP-MS) and silver staining were performed to identify LRP11-interacting proteins (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A, <xref rid="Fig6" ref-type="fig">B</xref>). RACK1 was identified as a potential binding partner. This interaction was subsequently confirmed through exogenous and endogenous co-immunoprecipitation (Co-IP) assays (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>C, <xref rid="Fig6" ref-type="fig">D</xref>). Molecular localization analysis revealed that residues 309&#x02013;500 of LRP11 specifically interact with the RACK1 (residues 91&#x02013;231) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>E, <xref rid="Fig6" ref-type="fig">G</xref>). These findings are further supported by docking simulation results, which provide additional evidence for the structural basis of the LRP11-RACK1 interaction (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>H).<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>LRP11 mediates RACK1 function at the post-translational level. <bold>A</bold> Identification of interacting proteins using sensitive silver staining. <bold>B</bold> Mass spectrometry revealed LRP11 -interacting proteins. <bold>C</bold> Co-IP assays were performed to investigate the interaction between endogenous LRP11 and RACK1.<bold> D</bold> Co-IP assays were conducted in HEK293T cells to investigate the interaction between exogenous LRP11 and RACK1.<bold> E</bold> Schematic diagram of LRP11 domains and its truncated mutants (top) and RACK1 domains and its truncated mutants (bottom). <bold>F&#x02013;G</bold> Co-IP assays were performed to investigate the binding regions between LRP11 and RACK1. <bold>H</bold> Schematic diagram of the binding sites between LRP11 and RACK1. <bold>I, J</bold> RACK1 mRNA and protein expression levels following LRP11 knockdown or overexpression. <bold>K-L</bold> RACK1 protein expression levels following LRP11 knockdown and treatment with CQ (10&#x000a0;&#x000b5;M,20&#x000a0;h) or MG132(10&#x000a0;&#x000b5;M,8&#x000a0;h). <bold>M</bold>&#x02013;<bold>N</bold> RACK1 protein expression levels in Huh7 or Hep3B cells after CHX (50&#x000a0;&#x003bc;g/ml)treatment for the indicated times. <bold>O</bold> Ubiquitination of RACK1 following LRP11 knockdown or overexpression. All data are expressed as the mean&#x02009;&#x000b1;&#x02009;SD of values from experiments performed in triplicate. *P&#x02009;&#x0003c;&#x02009;0.05, **P&#x02009;&#x0003c;&#x02009;0.01, ***P&#x02009;&#x0003c;&#x02009;0.001. n.s.&#x02009;=&#x02009;not significant</p></caption><graphic xlink:href="10020_2025_1097_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec16"><title>LRP11 mediates RACK1 function at the post-translational level</title><p id="Par24">To elucidate the mechanism by which LRP11 and RACK1 influence HCC progression, Western blot (F<xref rid="Fig6" ref-type="fig">i</xref>g.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>I) and RT-qPCR (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>J) were performed in HCC cells with LRP11 knockdown or overexpression. LRP11 knockdown inhibited RACK1 protein expression without affecting RACK1 mRNA levels, while LRP11 overexpression increased RACK1 protein expression, indicating that LRP11 regulates RACK1 at the post-translational level. In the presence of the protein synthesis inhibitor cycloheximide, RACK1 protein stability was enhanced in LRP11-overexpressing cells and reduced in LRP11-knockdown cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>M, <xref rid="Fig6" ref-type="fig">N</xref>). Furthermore, treatment with the proteasome inhibitor MG132, but not the lysosomal inhibitor chloroquine, reversed the reduction of RACK1 protein levels caused by LRP11 knockdown (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>K, <xref rid="Fig6" ref-type="fig">L</xref>), indicating that LRP11 may regulate RACK1 stability through the proteasomal degradation pathway. Moreover, LRP11 downregulation increased RACK1 ubiquitination, while LRP11 overexpression appeared to reduce it (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>O).</p></sec><sec id="Sec17"><title>LRP11 recruits USP5 to mediate RACK1 deubiquitination</title><p id="Par25">The results above indicate that LRP11 promotes RACK1 deubiquitination in HCC cells, despite not being a member of the deubiquitinase family. Thus, we hypothesized that LRP11 may regulate the interaction between RACK1 and its deubiquitinase. Based on this hypothesis, we identified USP5 as a candidate deubiquitinase for RACK1 through IP/MS screening. Immunofluorescence experiments demonstrated that LRP11 colocalizes and interacts with both RACK1 and USP5 in HCC cells (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A, Fig. S2G). These interactions were further confirmed by exogenous and endogenous Co-IP assays (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>B, <xref rid="Fig7" ref-type="fig">C</xref>, Fig. S2H-I). While our results confirmed the interaction between RACK1 and USP5, it was still uncertain whether USP5 directly mediates RACK1 deubiquitination, prompting further investigation. RT-qPCR and Western blotting revealed that USP5 knockdown decreased RACK1 protein levels without affecting RACK1 mRNA levels, confirming that USP5 regulates RACK1 at the post-translational level (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>D). Upon CHX treatment, RACK1 protein stability increased in USP5-overexpressing cells (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>E, <xref rid="Fig7" ref-type="fig">F</xref>), and USP5 overexpression suppressed RACK1 ubiquitination (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>G). Importantly, When LRP11 is downregulated, the binding ability between USP5 and RACK1 is reduced. However, when LRP11 is overexpressed, the binding ability between USP5 and RACK1 is enhanced. LRP11 specifically promotes the interaction between USP5 and RACK1 (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>H). The ubiquitination experiments showed that the expression of USP5 reversed the increase in RACK1 ubiquitination induced by LRP11 knockdown, while also promoting the deubiquitination of RACK1 induced by LRP11 overexpression (F<xref rid="Fig7" ref-type="fig">i</xref>g.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>I). In summary, we propose that LRP11 acts as a scaffold, facilitating the interaction between RACK1 and USP5, forming a regulatory complex that promotes RACK1 deubiquitination and stability. This regulatory axis may play a critical role in the progression of HCC.<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>LRP11 recruits USP5 to mediate RACK1 deubiquitination.<bold> A</bold> Immunofluorescence of LRP11 (green), USP5(red)and RACK1 (red) in Huh7 cells. Scale bar, 20&#x000a0;&#x003bc;m. <bold>B</bold> Co-IP assays were performed to investigate the interaction between endogenous LRP11 and USP5.<bold> C</bold> Co-IP assays were performed to investigate the interaction between endogenous USP5 and RACK1. <bold>D</bold> RACK1 mRNA and protein expression levels following USP5 knockdown or overexpression. <bold>E</bold><bold>, </bold><bold>F</bold> RACK1 protein expression levels detected by Western blot in HCC cells treated with CHX and different plasmids. <bold>G</bold> Ubiquitination levels of RACK1 measured by Western blot after transfection with different plasmids. <bold>H</bold> Interaction between RACK1 and USP5 in LRP11 knockdown and overexpression cells. <bold>I</bold> Ubiquitination levels of RACK1 in LRP11 knockdown or overexpression cells with or without USP5. All data are expressed as the mean&#x02009;&#x000b1;&#x02009;SD of values from experiments performed in triplicate. *P&#x02009;&#x0003c;&#x02009;0.05, **P&#x02009;&#x0003c;&#x02009;0.01, ***P&#x02009;&#x0003c;&#x02009;0.001. n.s.&#x02009;=&#x02009;not significant</p></caption><graphic xlink:href="10020_2025_1097_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec18"><title>RACK1 and USP5 are critical for LRP11-mediated malignant phenotypes and metabolism in HCC</title><p id="Par26">To further validate the roles of RACK1 and USP5 in mediating LRP11-driven malignant phenotypes in HCC, we conducted rescue experiments to determine if overexpression of RACK1 or USP5 could reverse the effects of LRP11 knockdown. EdU (Fig. S3A) and colony formation assays (Fig. S3B) demonstrated that LRP11 knockdown impaired HCC cell proliferation. However, overexpression of RACK1 or USP5 effectively rescued this inhibitory effect, restoring cell proliferation to near-control levels. Similarly, Transwell (Fig. S3D) and wound healing assays (Fig. S3E) showed that LRP11 knockdown suppressed cell migration and invasion, which was reversed by RACK1 or USP5 overexpression. Furthermore, Nile red staining revealed that the LRP11 knockdown-induced reduction in lipid accumulation was rescued by RACK1 or USP5 overexpression (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>A), indicating their role in restoring lipid metabolism. Western blot analysis showed that RACK1 and USP5 overexpression restored the levels of key lipid metabolism proteins that had been reduced by LRP11 knockdown (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>B). This rescue effect was further confirmed by biochemical measurements of triglyceride and cholesterol levels (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>C, D). In vivo experiments further demonstrated that overexpression of RACK1 and USP5 alleviated the inhibitory effects of LRP11 knockdown on tumor proliferation, confirming their crucial role in mediating LRP11-driven HCC growth (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>E&#x02013;H). In summary, our rescue experiments suggest that LRP11 may contribute to HCC malignant progression through its interactions with USP5 and RACK1, identifying these proteins as potential mediators of LRP11-associated oncogenic processes and as possible therapeutic targets for further investigation in HCC.<fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>RACK1 and USP5 are critical for LRP11-mediated malignant phenotypes and metabolism in HCC.<bold> A</bold> Measurement of neutral lipids in Huh7 cells transfected with sh-NC, sh-LRP11#2, sh-LRP11#2&#x02009;+&#x02009;RACK1-OE, and sh-LRP11#2&#x02009;+&#x02009;USP5-OE plasmids using Nile red and DAPI double staining. Scale bar, 50&#x000a0;&#x003bc;m. This was followed by quantifying the mean fluorescence intensity of Nile red staining for each cell line. <bold>B</bold> Measurement of lipogenic enzyme protein levels in Huh7 cells transfected with different plasmids using Western blotting. <bold>C</bold>, <bold>D</bold> Measurement of triglyceride and cholesterol levels in Huh7 cells.<bold> E</bold> Images of subcutaneous xenograft tumors from Huh7 (sh-NC, sh-LRP11#2, sh-LRP11#2&#x02009;+&#x02009;RACK1-OE, sh-LRP11#2&#x02009;+&#x02009;USP5-OE) cells. <bold>F</bold> Weight of the subcutaneous tumors. <bold>G</bold> Subcutaneous tumor volume growth curve. <bold>H</bold> H&#x00026;E, Ki67, LRP11 IHC staining, and Nile red staining in xenograft tumors. Scale bar, 50&#x000a0;&#x003bc;m. All data are expressed as the mean&#x02009;&#x000b1;&#x02009;SD of values from experiments performed in triplicate. *P&#x02009;&#x0003c;&#x02009;0.05, **P&#x02009;&#x0003c;&#x02009;0.01, ***P&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="10020_2025_1097_Fig8_HTML" id="MO8"/></fig></p></sec></sec><sec id="Sec19"><title>Discussion</title><p id="Par27">HCC, as one of the most common and highly malignant tumors worldwide, is associated with high incidence and mortality (Sung et al. <xref ref-type="bibr" rid="CR27">2021</xref>). Therefore, understanding the mechanisms driving the malignant progression of HCC is of paramount importance. This study provides novel insights into the potential oncogenic role of LRP11 in HCC and suggests that the interaction between LRP11 and RACK1 may contribute to HCC progression.</p><p id="Par28">In this study, we found that higher LRP11 expression correlates with poorer clinical outcomes, indicating a potential tumor-promoting role for LRP11 in HCC. Analysis of LRP11 expression in HCC cells and tumor tissues revealed elevated levels compared to normal tissues. Although lower expression of LRP11 was observed in some HCC tissues, this may be influenced by factors such as tumor heterogeneity and changes in the tumor microenvironment. Therefore, the low expression of LRP11 in certain tumor tissues does not necessarily indicate a complete loss of its oncogenic function, but may reflect adaptive changes in tumor cells in response to the microenvironment or growth conditions. Functional assays in vitro and in vivo demonstrated that LRP11 overexpression significantly promotes HCC cell proliferation, migration, and invasion, while LRP11 knockdown had the opposite effects. Additionally, in both xenograft and lung metastasis models, LRP11 overexpression markedly enhanced tumor growth, invasion, and metastasis, providing additional support for its potential oncogenic role in HCC.</p><p id="Par29">Lipid metabolism is a crucial component of tumor metabolism. Unlike normal human cells that rely on exogenous fatty acids, cancer cells preferentially synthesize lipids de novo to support their rapid proliferation (Medes et al. <xref ref-type="bibr" rid="CR17">1953</xref>). Studies have shown that aberrant lipid metabolism is a key feature of HCC. Elevated expression of genes associated with fatty acid (FA) biosynthesis in HCC tissues suggests that lipid metabolism plays a role in the pathogenesis of HCC (Berndt et al. <xref ref-type="bibr" rid="CR1">2019</xref>). FASN, ACACA, ACLY, and ACSL4 are considered key enzymes in lipid metabolism, and previous studies have shown that they can promote the proliferation of various cancers (Wei et al. <xref ref-type="bibr" rid="CR31">2023</xref>; Wang et al. <xref ref-type="bibr" rid="CR29">2010</xref>; Khwairakpam et al. <xref ref-type="bibr" rid="CR10">2015</xref>; Menendez and Lupu <xref ref-type="bibr" rid="CR18">2007</xref>; Quan et al. <xref ref-type="bibr" rid="CR23">2021</xref>). However, the mechanisms by which lipid metabolism functions in HCC cells remain unclear. A better understanding of fatty acid synthesis in HCC could help develop new therapeutic strategies for this malignancy. Through RNA sequencing, we found that LRP11 regulates a specific set of genes related to FA metabolism. The increase in fatty acid levels may provide energy for the uncontrolled proliferation of HCC cells (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>).<fig id="Fig9"><label>Fig.&#x000a0;9</label><caption><p>Diagram of the molecular mechanism</p></caption><graphic xlink:href="10020_2025_1097_Fig9_HTML" id="MO9"/></fig></p><p id="Par30">Mechanistic studies further demonstrated that LRP11 may promote tumorigenesis by interacting with RACK1 and stabilizing its protein levels through deubiquitination. RACK1, a highly conserved WD-repeat protein, is known to be dysregulated in multiple cancers. Previous research has shown that RACK1 can act as either a tumor suppressor or an oncogene, depending on the cancer type (Deng et al. <xref ref-type="bibr" rid="CR4">2012</xref>; Xiao et al. <xref ref-type="bibr" rid="CR34">2018</xref>), Moreover, elevated RACK1 expression promotes the malignant progression of HCC (Duan et al. <xref ref-type="bibr" rid="CR5">2018</xref>). This is the first study to identify the interaction between LRP11 and RACK1, contributing to the maintenance of RACK1 protein stability. Subsequent studies revealed that the 309&#x02013;500 amino acid region of LRP11 is responsible for binding to the homologous domain of RACK1 (residues 91&#x02013;231). Reducing LRP11 increases RACK1 ubiquitination and accelerates its degradation. These findings provide new insights into the mechanism by which LRP11 may contribute to HCC progression.</p><p id="Par31">Ubiquitination is a post-translational modification that affects protein stability, intracellular transport, and enzyme activity, playing a critical role in regulating cellular functions. USP5 interacts with PD-1, leading to its deubiquitination and stabilization, thereby modulating tumor immunotherapy (Xiao et al. <xref ref-type="bibr" rid="CR35">2023</xref>). USP5 deubiquitination activity interacts with and stabilizes SLUG, thereby regulating its abundance in epithelial-mesenchymal transition (EMT) in HCC (Meng et al. <xref ref-type="bibr" rid="CR19">2019</xref>). Our findings attribute the stability of RACK1 to the regulation mediated by LRP11 through USP5. However, the specific binding sites between USP5 and RACK1 remain unclear, and it is uncertain whether other factors are involved in the regulation of RACK1 by LRP11. Whether these findings can be translated into clinical applications, such as therapeutic targets or diagnostic biomarkers, requires further clinical research to verify their efficacy and safety. These questions warrant additional experimental investigation.</p><p id="Par32">In conclusion, our study suggests that LRP11 may play a role in promoting lipid metabolism, proliferation, migration, and invasion in HCC. Mechanistically, LRP11 appears to directly bind to RACK1 and enhance its stability by promoting deubiquitination through the recruitment of USP5, thereby potentially facilitating HCC lipid metabolism and progression. These findings indicate that LRP11 could be explored as a therapeutic target for HCC, although further research is needed to fully validate its clinical potential.</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10020_2025_1097_MOESM1_ESM.docx"><caption><p>Additional file 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="10020_2025_1097_MOESM2_ESM.docx"><caption><p>Additional file 2.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="10020_2025_1097_MOESM3_ESM.docx"><caption><p>Additional file 3.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>LRP11</term><def><p id="Par2">LDL receptor related protein 11</p></def></def-item><def-item><term>RACK1</term><def><p id="Par3">Receptor for activated C kinase 1</p></def></def-item><def-item><term>USP5</term><def><p id="Par4">Ubiquitin specific peptidase 5</p></def></def-item><def-item><term>TCGA</term><def><p id="Par5">The Cancer Genome Atlas</p></def></def-item><def-item><term>PVDF</term><def><p id="Par6">Polyvinylidene Difluoride</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Litao Liang, Wenbo Jia and Jinyi Wang contribute equally to the study.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>LTL, WBJ, JYW, WZD designed the study. LTL, WBJ, JYW, WHZ, CX and YZF collated and analyzed the data. LTL, WBJ, JYW wrote the preliminary draft of the manuscript. LTL, WBJ, JYW, XYL QPL conducted experiments. XMA, LBK and WZD supervised the research and reviewed the manuscript. All authors read and approved this version of manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by grants from the National Natural Science Foundation of China (81871260); Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University (PY2022007).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The data used were obtained from the TCGA database and the UALCAN dataset. All data generated or analyzed during this study are contained in this paper or supplementary materials. Processed data are available from the corresponding author upon reasonable request. No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par33">This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University. Informed consent was obtained from all patients in compliance with regional regulations. All animal experiments in this study were approved by the Institutional Animal Care and Use Committee of the First Affiliated Hospital of Nanjing Medical University (IACUC-2406029).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par34">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par35">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Berndt</surname><given-names>N</given-names></name><name><surname>Eckstein</surname><given-names>J</given-names></name><name><surname>Heucke</surname><given-names>N</given-names></name><name><surname>Gajowski</surname><given-names>R</given-names></name><name><surname>Stockmann</surname><given-names>M</given-names></name><name><surname>Meierhofer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Characterization of lipid and lipid droplet metabolism in human HCC</article-title><source>Cells</source><year>2019</year><pub-id pub-id-type="doi">10.3390/cells8050512</pub-id><pub-id pub-id-type="pmid">31137921</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Berndt N, Eckstein J, Heucke N, Gajowski R, Stockmann M, Meierhofer D, et al. Characterization of lipid and lipid droplet metabolism in human HCC. Cells. 2019. 10.3390/cells8050512.<pub-id pub-id-type="pmid">31137921</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Pei</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>RACK1 promotes self-renewal and chemoresistance of cancer stem cells in human hepatocellular carcinoma through stabilizing nanog</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>811</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.7150/thno.29271</pub-id><pub-id pub-id-type="pmid">30809310</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Cao J, Zhao M, Liu J, Zhang X, Pei Y, Wang J, et al. RACK1 promotes self-renewal and chemoresistance of cancer stem cells in human hepatocellular carcinoma through stabilizing nanog. Theranostics. 2019;9:811&#x02013;28. 10.7150/thno.29271.<pub-id pub-id-type="pmid">30809310</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Dan</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Yin</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><etal/></person-group><article-title>RACK1 promotes cancer progression by increasing the M2/M1 macrophage ratio via the NF-&#x003ba;B pathway in oral squamous cell carcinoma</article-title><source>Mol Oncol</source><year>2020</year><volume>14</volume><fpage>795</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12644</pub-id><pub-id pub-id-type="pmid">31997535</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Dan H, Liu S, Liu J, Liu D, Yin F, Wei Z, et al. RACK1 promotes cancer progression by increasing the M2/M1 macrophage ratio via the NF-&#x003ba;B pathway in oral squamous cell carcinoma. Mol Oncol. 2020;14:795&#x02013;807. 10.1002/1878-0261.12644.<pub-id pub-id-type="pmid">31997535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>YZ</given-names></name><name><surname>Yao</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Mao</surname><given-names>ZF</given-names></name><name><surname>Hu</surname><given-names>PT</given-names></name><name><surname>Long</surname><given-names>LY</given-names></name><etal/></person-group><article-title>RACK1 suppresses gastric tumorigenesis by stabilizing the &#x003b2;-catenin destruction complex</article-title><source>Gastroenterology</source><year>2012</year><volume>142</volume><fpage>812</fpage><lpage>823.e815</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.12.046</pub-id><pub-id pub-id-type="pmid">22240482</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Deng YZ, Yao F, Li JJ, Mao ZF, Hu PT, Long LY, et al. RACK1 suppresses gastric tumorigenesis by stabilizing the &#x003b2;-catenin destruction complex. Gastroenterology. 2012;142:812-823.e815. 10.1053/j.gastro.2011.12.046.<pub-id pub-id-type="pmid">22240482</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Jia</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis</article-title><source>J Hepatol</source><year>2018</year><volume>68</volume><fpage>1191</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.02.003</pub-id><pub-id pub-id-type="pmid">29454068</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Duan F, Wu H, Jia D, Wu W, Ren S, Wang L, et al. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis. J Hepatol. 2018;68:1191&#x02013;202. 10.1016/j.jhep.2018.02.003.<pub-id pub-id-type="pmid">29454068</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Duff</surname><given-names>D</given-names></name><name><surname>Long</surname><given-names>A</given-names></name></person-group><article-title>Roles for RACK1 in cancer cell migration and invasion</article-title><source>Cell Signal</source><year>2017</year><volume>35</volume><fpage>250</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2017.03.005</pub-id><pub-id pub-id-type="pmid">28336233</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Duff D, Long A. Roles for RACK1 in cancer cell migration and invasion. Cell Signal. 2017;35:250&#x02013;5. 10.1016/j.cellsig.2017.03.005.<pub-id pub-id-type="pmid">28336233</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><etal/></person-group><article-title>LRP11 activates &#x003b2;-catenin to induce PD-L1 expression in prostate cancer</article-title><source>J Drug Target</source><year>2020</year><volume>28</volume><fpage>508</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1080/1061186x.2019.1687710</pub-id><pub-id pub-id-type="pmid">31865764</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Gan S, Ye J, Li J, Hu C, Wang J, Xu D, et al. LRP11 activates &#x003b2;-catenin to induce PD-L1 expression in prostate cancer. J Drug Target. 2020;28:508&#x02013;15. 10.1080/1061186x.2019.1687710.<pub-id pub-id-type="pmid">31865764</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Pan</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>F</given-names></name><etal/></person-group><article-title>An integrative pan-cancer analysis illustrating the key role of LRP11 in cervical cancer</article-title><source>Medicine (Baltimore)</source><year>2023</year><volume>102</volume><fpage>e33201</fpage><pub-id pub-id-type="doi">10.1097/md.0000000000033201</pub-id><pub-id pub-id-type="pmid">36930084</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Gu F, Xu F, Pan Z, Shi L, Yu J, Song F, et al. An integrative pan-cancer analysis illustrating the key role of LRP11 in cervical cancer. Medicine (Baltimore). 2023;102: e33201. 10.1097/md.0000000000033201.<pub-id pub-id-type="pmid">36930084</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>R</given-names></name></person-group><article-title>FUT2 inhibits the EMT and metastasis of colorectal cancer by increasing LRP1 fucosylation</article-title><source>Cell Commun Signal</source><year>2023</year><volume>21</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.1186/s12964-023-01060-0</pub-id><pub-id pub-id-type="pmid">36973740</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">He L, Guo Z, Wang W, Tian S, Lin R. FUT2 inhibits the EMT and metastasis of colorectal cancer by increasing LRP1 fucosylation. Cell Commun Signal. 2023;21:63. 10.1186/s12964-023-01060-0.<pub-id pub-id-type="pmid">36973740</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Khwairakpam</surname><given-names>AD</given-names></name><name><surname>Shyamananda</surname><given-names>MS</given-names></name><name><surname>Sailo</surname><given-names>BL</given-names></name><name><surname>Rathnakaram</surname><given-names>SR</given-names></name><name><surname>Padmavathi</surname><given-names>G</given-names></name><name><surname>Kotoky</surname><given-names>J</given-names></name><etal/></person-group><article-title>ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment</article-title><source>Curr Drug Targets</source><year>2015</year><volume>16</volume><fpage>156</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.2174/1389450115666141224125117</pub-id><pub-id pub-id-type="pmid">25537655</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Khwairakpam AD, Shyamananda MS, Sailo BL, Rathnakaram SR, Padmavathi G, Kotoky J, et al. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment. Curr Drug Targets. 2015;16:156&#x02013;63. 10.2174/1389450115666141224125117.<pub-id pub-id-type="pmid">25537655</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name></person-group><article-title>RACK1, a versatile hub in cancer</article-title><source>Oncogene</source><year>2015</year><volume>34</volume><fpage>1890</fpage><lpage>1898</lpage><pub-id pub-id-type="doi">10.1038/onc.2014.127</pub-id><pub-id pub-id-type="pmid">24882575</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Li JJ, Xie D. RACK1, a versatile hub in cancer. Oncogene. 2015;34:1890&#x02013;8. 10.1038/onc.2014.127.<pub-id pub-id-type="pmid">24882575</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group><article-title>OTUB1's role in promoting OSCC development by stabilizing RACK1 involves cell proliferation, migration, invasion, and tumor-associated macrophage M1 polarization</article-title><source>Cell Signal</source><year>2023</year><volume>110</volume><fpage>110835</fpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2023.110835</pub-id><pub-id pub-id-type="pmid">37532135</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Li Y, Li R, Qin H, He H, Li S. OTUB1&#x02019;s role in promoting OSCC development by stabilizing RACK1 involves cell proliferation, migration, invasion, and tumor-associated macrophage M1 polarization. Cell Signal. 2023;110: 110835. 10.1016/j.cellsig.2023.110835.<pub-id pub-id-type="pmid">37532135</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>W</given-names></name><etal/></person-group><article-title>LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer</article-title><source>Cancer Lett</source><year>2024</year><volume>593</volume><fpage>216807</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2024.216807</pub-id><pub-id pub-id-type="pmid">38462037</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Lin H, Fu L, Zhou X, Yu A, Chen Y, Liao W, et al. LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer. Cancer Lett. 2024;593: 216807. 10.1016/j.canlet.2024.216807.<pub-id pub-id-type="pmid">38462037</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Zha</surname><given-names>R</given-names></name><name><surname>Jalali</surname><given-names>A</given-names></name><etal/></person-group><article-title>Overexpression of Lrp5 enhanced the anti-breast cancer effects of osteocytes in bone</article-title><source>Bone Res</source><year>2021</year><volume>9</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1038/s41413-021-00152-2</pub-id><pub-id pub-id-type="pmid">34230453</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Liu S, Wu D, Sun X, Fan Y, Zha R, Jalali A, et al. Overexpression of Lrp5 enhanced the anti-breast cancer effects of osteocytes in bone. Bone Res. 2021;9:32. 10.1038/s41413-021-00152-2.<pub-id pub-id-type="pmid">34230453</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Bukhari</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Ren</surname><given-names>F</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Enhanced LRP8 expression induced by Helicobacter pylori drives gastric cancer progression by facilitating &#x003b2;-Catenin nuclear translocation</article-title><source>J Adv Res</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.jare.2024.04.002</pub-id><pub-id pub-id-type="pmid">39743214</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Liu B, Bukhari I, Li F, Ren F, Xia X, Hu B, et al. Enhanced LRP8 expression induced by Helicobacter pylori drives gastric cancer progression by facilitating &#x003b2;-Catenin nuclear translocation. J Adv Res. 2024. 10.1016/j.jare.2024.04.002.<pub-id pub-id-type="pmid">39743214</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Kelley</surname><given-names>RK</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Singal</surname><given-names>AG</given-names></name><name><surname>Pikarsky</surname><given-names>E</given-names></name><name><surname>Roayaie</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hepatocellular Carcinoma</article-title><source>Nat Rev Dis Primers</source><year>2021</year><volume>7</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1038/s41572-020-00240-3</pub-id><pub-id pub-id-type="pmid">33479224</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular Carcinoma. Nat Rev Dis Primers. 2021;7:6. 10.1038/s41572-020-00240-3.<pub-id pub-id-type="pmid">33479224</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Medes</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Weinhouse</surname><given-names>S</given-names></name></person-group><article-title>Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro</article-title><source>Cancer Res</source><year>1953</year><volume>13</volume><fpage>27</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">13032945</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953;13:27&#x02013;9.<pub-id pub-id-type="pmid">13032945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Menendez</surname><given-names>JA</given-names></name><name><surname>Lupu</surname><given-names>R</given-names></name></person-group><article-title>Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>763</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1038/nrc2222</pub-id><pub-id pub-id-type="pmid">17882277</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763&#x02013;77. 10.1038/nrc2222.<pub-id pub-id-type="pmid">17882277</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Ai</surname><given-names>X</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Qian</surname><given-names>B</given-names></name><name><surname>Qiao</surname><given-names>K</given-names></name><etal/></person-group><article-title>USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>573</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.7150/thno.27654</pub-id><pub-id pub-id-type="pmid">30809294</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Meng J, Ai X, Lei Y, Zhong W, Qian B, Qiao K, et al. USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma. Theranostics. 2019;9:573&#x02013;87. 10.7150/thno.27654.<pub-id pub-id-type="pmid">30809294</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xi</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><etal/></person-group><article-title>MYO10 contributes to the malignant phenotypes of colorectal cancer via RACK1 by activating integrin/Src/FAK signaling</article-title><source>Cancer Sci</source><year>2022</year><volume>113</volume><fpage>3838</fpage><lpage>3851</lpage><pub-id pub-id-type="doi">10.1111/cas.15519</pub-id><pub-id pub-id-type="pmid">35912545</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ou H, Wang L, Xi Z, Shen H, Jiang Y, Zhou F, et al. MYO10 contributes to the malignant phenotypes of colorectal cancer via RACK1 by activating integrin/Src/FAK signaling. Cancer Sci. 2022;113:3838&#x02013;51. 10.1111/cas.15519.<pub-id pub-id-type="pmid">35912545</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name></person-group><article-title>OTUB1 accelerates hepatocellular carcinoma by stabilizing RACK1 via its non-canonical ubiquitination</article-title><source>Cell Oncol (Dordr)</source><year>2024</year><volume>47</volume><fpage>987</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1007/s13402-023-00913-7</pub-id><pub-id pub-id-type="pmid">38315284</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Peng L, Wu T, Liu Y, Zhao D, He W, Yuan Y. OTUB1 accelerates hepatocellular carcinoma by stabilizing RACK1 via its non-canonical ubiquitination. Cell Oncol (Dordr). 2024;47:987&#x02013;1004. 10.1007/s13402-023-00913-7.<pub-id pub-id-type="pmid">38315284</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Pi</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><etal/></person-group><article-title>Loss of SMURF2 expression enhances RACK1 stability and promotes ovarian cancer progression</article-title><source>Cell Death Differ</source><year>2023</year><volume>30</volume><fpage>2382</fpage><lpage>2392</lpage><pub-id pub-id-type="doi">10.1038/s41418-023-01226-w</pub-id><pub-id pub-id-type="pmid">37828084</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Pi Y, Feng Q, Sun F, Wang Z, Zhao Y, Chen D, et al. Loss of SMURF2 expression enhances RACK1 stability and promotes ovarian cancer progression. Cell Death Differ. 2023;30:2382&#x02013;92. 10.1038/s41418-023-01226-w.<pub-id pub-id-type="pmid">37828084</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>J</given-names></name><name><surname>Bode</surname><given-names>AM</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name></person-group><article-title>ACSL family: The regulatory mechanisms and therapeutic implications in cancer</article-title><source>Eur J Pharmacol</source><year>2021</year><volume>909</volume><fpage>174397</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174397</pub-id><pub-id pub-id-type="pmid">34332918</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Quan J, Bode AM, Luo X. ACSL family: The regulatory mechanisms and therapeutic implications in cancer. Eur J Pharmacol. 2021;909: 174397. 10.1016/j.ejphar.2021.174397.<pub-id pub-id-type="pmid">34332918</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><etal/></person-group><article-title>SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/&#x003b2;-catenin signaling</article-title><source>Oncogene</source><year>2022</year><volume>41</volume><fpage>2390</fpage><lpage>2403</lpage><pub-id pub-id-type="doi">10.1038/s41388-022-02259-0</pub-id><pub-id pub-id-type="pmid">35277657</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Rong Z, Zhang L, Li Z, Xiao Z, Duan Y, Ren X, et al. SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/&#x003b2;-catenin signaling. Oncogene. 2022;41:2390&#x02013;403. 10.1038/s41388-022-02259-0.<pub-id pub-id-type="pmid">35277657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Roslan</surname><given-names>Z</given-names></name><name><surname>Muhamad</surname><given-names>M</given-names></name><name><surname>Selvaratnam</surname><given-names>L</given-names></name><name><surname>Ab-Rahim</surname><given-names>S</given-names></name></person-group><article-title>The roles of low-density lipoprotein receptor-related proteins 5, 6, and 8 in cancer: a review</article-title><source>J Oncol</source><year>2019</year><volume>2019</volume><fpage>4536302</fpage><pub-id pub-id-type="doi">10.1155/2019/4536302</pub-id><pub-id pub-id-type="pmid">31031810</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Roslan Z, Muhamad M, Selvaratnam L, Ab-Rahim S. The roles of low-density lipoprotein receptor-related proteins 5, 6, and 8 in cancer: a review. J Oncol. 2019;2019:4536302. 10.1155/2019/4536302.<pub-id pub-id-type="pmid">31031810</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Schapira</surname><given-names>M</given-names></name><name><surname>Tyers</surname><given-names>M</given-names></name><name><surname>Torrent</surname><given-names>M</given-names></name><name><surname>Arrowsmith</surname><given-names>CH</given-names></name></person-group><article-title>WD40 repeat domain proteins: a novel target class?</article-title><source>Nat Rev Drug Discov</source><year>2017</year><volume>16</volume><fpage>773</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.179</pub-id><pub-id pub-id-type="pmid">29026209</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Schapira M, Tyers M, Torrent M, Arrowsmith CH. WD40 repeat domain proteins: a novel target class? Nat Rev Drug Discov. 2017;16:773&#x02013;86. 10.1038/nrd.2017.179.<pub-id pub-id-type="pmid">29026209</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209&#x02013;49. 10.3322/caac.21660.<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Zuo</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>RACK1 facilitates breast cancer progression by competitively inhibiting the binding of &#x003b2;-catenin to PSMD2 and enhancing the stability of &#x003b2;-catenin</article-title><source>Cell Death Dis</source><year>2023</year><volume>14</volume><fpage>685</fpage><pub-id pub-id-type="doi">10.1038/s41419-023-06191-3</pub-id><pub-id pub-id-type="pmid">37848434</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Tian R, Tian J, Zuo X, Ren S, Zhang H, Liu H, et al. RACK1 facilitates breast cancer progression by competitively inhibiting the binding of &#x003b2;-catenin to PSMD2 and enhancing the stability of &#x003b2;-catenin. Cell Death Dis. 2023;14:685. 10.1038/s41419-023-06191-3.<pub-id pub-id-type="pmid">37848434</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Rajput</surname><given-names>S</given-names></name><name><surname>Watabe</surname><given-names>K</given-names></name><name><surname>Liao</surname><given-names>DF</given-names></name><name><surname>Cao</surname><given-names>D</given-names></name></person-group><article-title>Acetyl-CoA carboxylase-a as a novel target for cancer therapy</article-title><source>Front Biosci (Schol Ed)</source><year>2010</year><volume>2</volume><fpage>515</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.2741/s82</pub-id><pub-id pub-id-type="pmid">20036965</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Wang C, Rajput S, Watabe K, Liao DF, Cao D. Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci (Schol Ed). 2010;2:515&#x02013;26. 10.2741/s82.<pub-id pub-id-type="pmid">20036965</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><etal/></person-group><article-title>CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway</article-title><source>Cell Commun Signal</source><year>2022</year><volume>20</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/s12964-021-00818-8</pub-id><pub-id pub-id-type="pmid">35101055</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Wang A, Yang W, Li Y, Zhang Y, Zhou J, Zhang R, et al. CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway. Cell Commun Signal. 2022;20:16. 10.1186/s12964-021-00818-8.<pub-id pub-id-type="pmid">35101055</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Qin</surname><given-names>B</given-names></name><name><surname>Wen</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>FBXW7&#x003b2; loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><fpage>187</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01405-8</pub-id><pub-id pub-id-type="pmid">37202390</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Wei W, Qin B, Wen W, Zhang B, Luo H, Wang Y, et al. FBXW7&#x003b2; loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth. Signal Transduct Target Ther. 2023;8:187. 10.1038/s41392-023-01405-8.<pub-id pub-id-type="pmid">37202390</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group><article-title>RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1</article-title><source>Cancer Lett</source><year>2020</year><volume>469</volume><fpage>287</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2019.11.002</pub-id><pub-id pub-id-type="pmid">31705928</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Wu H, Song S, Yan A, Guo X, Chang L, Xu L, et al. RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1. Cancer Lett. 2020;469:287&#x02013;300. 10.1016/j.canlet.2019.11.002.<pub-id pub-id-type="pmid">31705928</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name></person-group><article-title>TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK/ERK signaling</article-title><source>Cell Death Dis</source><year>2023</year><volume>14</volume><fpage>529</fpage><pub-id pub-id-type="doi">10.1038/s41419-023-06048-9</pub-id><pub-id pub-id-type="pmid">37591850</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Xia K, Zheng D, Wei Z, Liu W, Guo W. TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK/ERK signaling. Cell Death Dis. 2023;14:529. 10.1038/s41419-023-06048-9.<pub-id pub-id-type="pmid">37591850</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>SS</given-names></name><name><surname>Li</surname><given-names>XH</given-names></name><name><surname>Xiao</surname><given-names>ZQ</given-names></name><etal/></person-group><article-title>RACK1 promotes tumorigenicity of colon cancer by inducing cell autophagy</article-title><source>Cell Death Dis</source><year>2018</year><volume>9</volume><fpage>1148</fpage><pub-id pub-id-type="doi">10.1038/s41419-018-1113-9</pub-id><pub-id pub-id-type="pmid">30451832</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Xiao T, Zhu W, Huang W, Lu SS, Li XH, Xiao ZQ, et al. RACK1 promotes tumorigenicity of colon cancer by inducing cell autophagy. Cell Death Dis. 2018;9:1148. 10.1038/s41419-018-1113-9.<pub-id pub-id-type="pmid">30451832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Bu</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><etal/></person-group><article-title>ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>2859</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-38605-3</pub-id><pub-id pub-id-type="pmid">37208329</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Xiao X, Shi J, He C, Bu X, Sun Y, Gao M, et al. ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nat Commun. 2023;14:2859. 10.1038/s41467-023-38605-3.<pub-id pub-id-type="pmid">37208329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>W</given-names></name><etal/></person-group><article-title>A novel UBE2T inhibitor suppresses Wnt/&#x003b2;-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination</article-title><source>Oncogene</source><year>2021</year><volume>40</volume><fpage>1027</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-01572-w</pub-id><pub-id pub-id-type="pmid">33323973</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Yu Z, Jiang X, Qin L, Deng H, Wang J, Ren W, et al. A novel UBE2T inhibitor suppresses Wnt/&#x003b2;-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene. 2021;40:1027&#x02013;42. 10.1038/s41388-020-01572-w.<pub-id pub-id-type="pmid">33323973</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>